Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

NCT00390325 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Hereditary Thyroid Gland Medullary Carcinoma
Locally Advanced Thyroid Gland Medullary Carcinoma
Multiple Endocrine Neoplasia Type 2A
Multiple Endocrine Neoplasia Type 2B
Recurrent Thyroid Gland Medullary Carcinoma
Sporadic Thyroid Gland Medullary Carcinoma
Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7

Interventions

DRUG: Sorafenib Tosylate

Sponsor

National Cancer Institute (NCI)